David L. Vesely, M.D., Ph.D.
Biographical Sketch | Interests | Current Research | Major Publications
M.D., University of Arizona
Ph.D., University of Arizona
Biographical Sketch
Interests
cardiovascular hormones
mechanism's of action and use in the diagnosis and treatment of cardiovascular disease, renal disease, and cancer
Current Research
David L. Vesely, M.D. Ph.D.'s investigations focus upon cardiovascular hormones that help regulate blood pressure and blood volume. Recent investigations have revealed that these peptide hormones may have beneficial effects to treat cancer. Vessel dilator, long acting natriuretic peptide, kaliuretic peptide, and atrial natriuretic peptide decrease the number of prostate cancer cells to 97.4% within 24 hours. They also decrease DNA synthesis greater than 90% in human breast, prostate and pancreatic adenocarcinomas as well as human small-cell and squamous cell lung cancer cells (1,2). When infused into athymic mice they completely stop the growth of human pancreatic adenocarcinomas and decrease the volume of this human cancer up to 49% in one week (3). Currently with surgery and cancer chemotherapy persons with pancreatic adenocarcinomas have a median survival of four months.
Major Publications
Vesely, B.A., McAfee, Q., Gower, W.R., Jr., and Vesely, D.L.: Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur. J. Clin. Invest. 33:998-1005, 2003.
Vesely B.A., Song S., Sanchez-Ramos J., Fitz S.R., Solivan S.M., Gower W.R. Jr., and Vesely D.L. Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur. J. Clin. Invest. 35:60-69, 2005.
Vesely, D.L. Clark, L.C., Garces, A.H., McAfee, Q.W., Soto, J., and Gower, W.R., Jr.: Novel therapeutic approach for cancer using four cardiovascular hormones. Eur. J. Clin. Invest. 34:674-682, 2004.
Saba, S.R and Vesely, DL: Cardiac natiruretic peptides: Hormones with anticancer effects that locolize to nucleus, cytoplasm, endothelium and fibroblasts of human cancers.
Histology & Histopathology 21:775-783, 2006
Sun. Y., Eichelbaum E.J., Wang, H., and Vesely, D.L.: Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in humanprostate caner cells. Anticancer Res 26: in press, 2006.